Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045669 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
A Phase 2 study, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00045669 is a Phase 2 study that has completed, run by University Health Network, Toronto. The registered enrollment target is 16 participants.
The verdict
NCT00045669, a Phase 2 study, has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have unresectable and/or metastatic salivary gland cancer.
Interventions
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045669
The ClinicalTrials.gov registry entry for NCT00045669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT00045669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045669 about?
NCT00045669 is a clinical study titled "Imatinib Mesylate in Treating Patients With Salivary Gland Cancer". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have unresectable and/or metastatic salivary gland cancer.
What is the current status of trial NCT00045669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2002-07. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00045669?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00045669?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.